VOR

Vor Biopharma Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K covers events occurring on May 22, 2025, regarding Vor Biopharma Inc.'s 2025 Annual Meeting of Stockholders. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol VOR.

Key Financial Metrics

This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the company's most recent Form 10-K or 10-Q for financial statements.

Material Changes and Corporate Actions

• Authorized Share Increase: Stockholders approved an amendment to the Amended and Restated Certificate of Incorporation, increasing the number of authorized common shares from 400,000,000 to 800,000,000. The amendment was filed with the Delaware Secretary of State on May 22, 2025.
• Meeting Participation: Approximately 58.7% of entitled shares (73,237,222 shares) were represented at the Annual Meeting.

Voting Results and Management Commentary

Stockholders voted on three proposals at the Annual Meeting:

1. Election of Directors: Matthew Patterson and Daniella Beckman were elected as Class I Directors to serve until the 2028 Annual Meeting.
   • Matthew Patterson: 53,425,286 votes For; 7,985,245 votes Withheld.
   • Daniella Beckman: 52,730,527 votes For; 8,680,004 votes Withheld.
2. Amendment to Certificate of Incorporation: Approved with 65,494,673 votes For, 7,657,942 votes Against, and 84,607 Abstentions.
3. Ratification of Auditors: Ernst & Young LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2025, with 73,065,960 votes For, 71,039 votes Against, and 100,223 Abstentions.

The filing contains no specific management commentary on risks, contingencies, or unusual items beyond the standard disclosure of the voting outcomes and the share authorization amendment.

Key Facts for Investor Verification

• Verify the effective date of the share authorization increase (May 22, 2025) and the new total authorized share count (800,000,000).
• Confirm the tenure of the newly elected directors (Matthew Patterson and Daniella Beckman) extending to the 2028 Annual Meeting.
• Review the definitive proxy statement (Schedule 14A) filed on April 8, 2025, for detailed background on the proposals.
• Note that this filing does not contain updated financial results; check recent 10-Q/10-K filings for liquidity and cash position.